Considering the impact COVID-19 could have on those with multiple sclerosis, we were delighted to speak with Dr Asaff Harel (Lennox Hill Hospital, New York, NY, USA) on the subject.
Questions
1. How does multiple sclerosis (MS) increase the risk from COVID-19? (00:06)
2. What advice are you giving to patients taking disease-modifying therapies for MS, particularly cell-depleting therapies such as ocrelizumab or rituximab? (01:56)
3. In what circumstances would you advise delaying the start of MS treatment in treatment-naïve patients? (05:29)
4. What advice are you giving to patients taking steroids for MS relapses? (08:18)
5. If the pandemic lasts for months, how will you address the challenges of managing patients in the intermediate or long-term, especially those with highly active MS? (10:00)
Speaker disclosure: Dr Asaff Harel has no financial or non-financial relationships or activities to declare in relation to this video interview.
touchNEUROLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Commissioned, edited and supported by Touch Medical Media
Filmed on Thursday 9 April 2020.
